Cambridge BioMarketing Recognized with Recent Awards Celebrating Clinical and Marketing Innovation for Rare Disease Programs

Agency Ranks on Medical Marketing & Media’s “Agency 100”; Head of Creative Alisa Shakarian Named a 2019 PM360 ELITE Disrupter; Hermes Creative Awards Honor Digital Media Campaigns

CAMBRIDGE, Mass.--()--Cambridge BioMarketing, an Ashfield company, part of UDG Healthcare plc and the world’s leading rare disease agency, today announced it has been recognized with multiple industry accolades for its innovative and creative campaigns on behalf of the global rare disease community.

PM360, the premier information resource for marketing decision makers in the pharmaceutical and medical device sectors, has named Head of Creative Alisa Shakarian a 2019 PM360 ELITE Disrupter. Now in its fifth year, the PM360 ELITE represents the most influential people in the healthcare industry today. Winners were formally recognized at the annual Elite Awards Party on July 16 in New York City.

“Alisa has a unique flair for artistry and design, and brings fresh perspectives and creative ideas to all the campaigns she touches across the agency in ways that unite our approach to the rare experience,” said Alyse Sukalski, managing director of CB West. “She is also a fearless leader who thrives on disrupting the status quo and we couldn’t be more proud of her recognition!”

Cambridge BioMarketing has also been named a winner in four categories by the Hermes Creative Awards, an international competition for creative professionals involved in the concept and design of marketing and communications programs, recognizing the following campaigns:

Platinum Winners

  • Client: Kyowa, for
  • Category: Electronic Media / Social Media / Interactive Media / Website Overall (Informational)
  • Client: Intercept, for Intercept App Updates
  • Category: Electronic Media / Social Media / Interactive Media / Mobile & Web-Based Technology (Mobile App)

Gold Winners

  • Client: Kyowa, for
  • Category: Electronic Media / Social Media / Interactive Media / Mobile & Web-Based Technology (Microsite)
  • Campaign: Rare in Common, for Faces of Rare
  • Category: Print Media / Advertising (Outdoor)

“With an experienced and collaborative team, including members of our medical and strategy departments, we were well-equipped to build the best website for cutaneous T-cell lymphoma (CTCL) patients and their families,” said Sarah Espinal, director of strategic planning and insights at CB. “By determining what information was already available to the CTCL community, we were able to develop unique, targeted content and supplemental education around key misconceptions of the disease that is so crucial for patients and their families to understand. Working with a great team internally and at Kyowa, the process was not only fun but extremely rewarding.”

The agency was also named to the MM&M Agency 100 celebrating a year marked by client wins and successes, a new Boston headquarters and its data-driven approach to creating exceptional digital and omnichannel experiences through its recently branded RareID offering. The annual issue ranks the leading healthcare firms and consultancies with health practices, profiling revenue, growth and trends in healthcare marketing.

“We are honored to be recognized for the talented individuals at CB on the frontlines of innovating rare disease marketing and pushing the envelope when it comes to creativity,” continued Sukalski. “We attribute our continued success to the many faces that inspire our work from Boston to San Francisco and beyond, from across our client base and among the rare disease community of patients, caretakers and support networks.”

About Cambridge BioMarketing
Founded in 2001, Cambridge BioMarketing is a U.S.-based communications agency specializing in rare orphan diseases with over 100 employees. Headquartered in Cambridge, MA with offices in Oakland, CA, Cambridge BioMarketing is an industry leader in orphan drug launches, advising pharmaceutical companies with an integrated focus on both traditional healthcare professional (HCP) programs and direct-to-patient work. In partnering with predominantly pharmaceutical and biotech customers, the agency’s goal is to bring physicians, specialists, and patient communities together on behalf of clients to transform human health in the face of devastating, under-appreciated disease states. Cambridge BioMarketing’s primary service offerings include: launch readiness support; digital strategy; market analytics; integrated marketing; patient identification and acquisition; medical affairs support; line extensions and patient retention and adherence programs. For more information, please go to:

About Ashfield:
Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with our clients across Advisory, Healthcare Communications, Commercial, Patient Solutions and Medical Affairs to build creative, scalable and tailored health solutions that are executed flawlessly, to address our client’s challenges and deliver positive outcomes for patients. With 7,000 employees, the company operates in 25 countries, delivering services in more than 50 countries across Europe, North America, South America and Asia. It works with more than 250 businesses, including all of the world’s top 25 pharmaceutical companies.

Its mission is to partner with its clients, helping to improve lives by ensuring healthcare professionals and patients get the medicines, knowledge and support they need.

Ashfield provides strategic consulting, audit, advisory, healthcare communications, field and contact centre sales teams, in-home and contact centre clinical educators, medical information, pharmacovigilance (drug safety) and event management services. For more information, go to


PAN Communications, for Cambridge BioMarketing
Danielle Kirsch, 617-502-4300


PAN Communications, for Cambridge BioMarketing
Danielle Kirsch, 617-502-4300